Erivedge May Be The Gleevec Of Hedgehog Inhibitors
Executive Summary
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.
You may also be interested in...
Still Enriched By Partnership, Curis Faces Ongoing Risks In 2014
The Lexington, Mass.-based oncology specialist seeks to resume enrollment in a Phase I trial halted after a patient death, while a revenue-generating drug partnered with Genentech could soon have a new competitor.
To REMS Or Not To REMS? Erivedge Shows Division At FDA Over Oncology Risk Management
The review division and CDER senior staff supported approval of Genentech’s highly teratogenic, basal cell carcinoma treatment vismodegib without a Risk Evaluation and Mitigation Strategy, but the Division of Risk Management believed a communications plan should be carried out under a REMS for the first-in-class Hedgehog pathway inhibitor.
Roche Oncology Turns In A Third Quarter To Rival The Good Old Days
Roche put up improved sales figures reflecting a 9% increase in oncology sales so far in 2012 and elaborated on its plan for continued growth in the face of eventual generic competition.